15th Dec 2015 08:57
LONDON (Alliance News) - Gene and cell therapy company Oxford Biomedica PLC on Tuesday said it has appointed Lorenzo Tallarigo as its new non-executive chairman, effective from February 1, 2016.
Tallarigo is the former chairman of US-listed biopharmaceutical company Intercept Pharmaceuticals and was formerly the head of US drug company Eli Lilly's international business.
Oxford Biomedica shares were down 2.1% to 5.56 pence on Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica